Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 87c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 4, 2021 4:06 PM EDT To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide
In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized
Anticipated fourth quarter milestones include: topline sotrovimab intramuscular administration data, new hepatitis B data at AASLD and initial HIV vaccine immunology data
SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.
The third quarter was both rewarding and... More
